FOSTER CITY, CA--(MARKET WIRE)--Nov 5, 2008 -- SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN - News) today announced that it will present at the Rodman & Renshaw Global Investment Conference at the New York Palace Hotel. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update on Wednesday, November 12, 2008 at 12:00 pm ET.

To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone

SciClone Pharmaceuticals (NasdaqGM:SCLN - News) is a global biopharmaceutical company dedicated to developing and commercializing promising therapies for life-threatening diseases. SciClone's corporate infrastructure leverages diverse global resources to finance growth in multiple markets and fund development of its advanced pipeline of mid- to late-stage product candidates. SciClone's lead product, ZADAXIN®, is approved for sale in over 30 countries for the treatment of hepatitis B, hepatitis C, and certain immune-sensitive cancers. Sales of ZADAXIN grew by 14% in 2007, reaching $34 million in China alone. SciClone has several products in clinical development, consisting of thymalfasin for stage IV melanoma, RP101 for the treatment of pancreatic cancer, and SCV-07 for the treatment of HCV and oral mucositis; and, awaiting approval in China, DC Bead(TM), for the treatment of liver cancer. For additional information, please visit www.sciclone.com.

The information in Dr. Blobel's presentation may contain forward-looking statements including our statement regarding timing and expectations for an SCV-07 Phase 2B clinical trial. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These risks and uncertainties include the timing of clinical trial events such as patient enrollment, requirements of and future actions of the U.S. Food and Drug Administration, the fact that experimental data, clinical results derived from studies with animals or a limited group of patients, and comparisons with other clinical trials may not be predictive of the results of larger studies or indicative of the efficacy or safety of larger studies and clinical trials. Please also refer to other risks and uncertainties described in SciClone's filings with the Securities and Exchange Commission. All forward-looking statements are based on information currently available to SciClone, and SciClone assumes no obligation to update any such forward-looking statements.

     Corporate Contact:
     Ana Kapor
     SciClone Pharmaceuticals, Inc.
     650.358.3437
     Email Contact